New prices on old drugs and dropping products that offer little profit raise concern and anger over drug pricing strategies. Must innovation preclude affordability?
Want to dig deeper into drug pricing?
-
Article
Early Dialogue in EU: Integrating Regulatory & HTA Requirements
Read Now
Thomas Kühler
Global Forum -
Article
Problem with Current Proposals to Address High Medicare Part B Drug Prices
Read Now
Gregory W. Daniel
Therapeutic Innovation & Regulatory Science
Member-only content
-
Article
Lower Drug Prices in Canada? Pharmaceutical Policy in Canadian Federal Election
Read Now
Judith Glennie
Global Forum -
Podcast
Pricing Pitfalls in Prescription Drug Advertising
Listen Now
Micheline Awad, Wayne Pines -
Article
Access to High-Cost Technologies in Asia-Pacific
Read Now
Rebecca Trowman et al.
Global Forum -
Video
Improving Communication & Access to Meet Patient Needs
Watch Now
Sissy Pham, Thomas Bols -
Article
Tying Medicare Part B Drug Prices to International Reference Pricing Will Devastate R&D
Read Now
Duane Schulthess et al.
Therapeutic Innovation & Regulatory Science
Member-only content
-
Article
Off-Label Use of Antipsychotic Agents in Dementia: Evidence for Revision of Reimbursement
Read Now
Donatas Stakisaitis et al.
Therapeutic Innovation & Regulatory Science
Member-only content
Want to learn more?
Plan to attend our Advertising & Promotion Regulatory Affairs Conference in Washington, DC, or sessions in the Value & Access track at DIA Europe 2020 in Brussels, Belgium.